Alcobra Ltd. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference


TEL AVIV, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced that it will be presenting at the upcoming Cantor Fitzgerald 2nd Annual Healthcare Conference.

Date:  Tuesday, July 12  
Time:  10:15am Eastern Daylight Time
Location:  Le Parker Meridien, New York City

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX, a proprietary drug candidate, to treat cognitive disorders including ADHD and Fragile X. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.


            

Contact Data